Profound Medical (TSE:PRN) Trading 2.7% Higher

Shares of Profound Medical Corp. (TSE:PRN) rose 2.7% during mid-day trading on Friday . The company traded as high as C$15.64 and last traded at C$15.40. Approximately 12,696 shares traded hands during trading, an increase of 110% from the average daily volume of 6,040 shares. The stock had previously closed at C$15.00.

Profound Medical Stock Performance

The company has a market capitalization of C$376.22 million, a price-to-earnings ratio of -8.75 and a beta of 1.27. The company has a 50 day moving average price of C$11.85 and a 200 day moving average price of C$11.38. The company has a debt-to-equity ratio of 15.78, a quick ratio of 14.98 and a current ratio of 5.41.

Profound Medical (TSE:PRN) last announced its quarterly earnings results on Thursday, May 9th. The company reported C($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of C($0.41) by C$0.06. The firm had revenue of C$2.58 million during the quarter, compared to the consensus estimate of C$3.24 million. Equities research analysts predict that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.